NTAS120, a covalently-binding FGFR inhibitor (FGFRi), overcomes resistance to BGJ398 in patients with FGFR2 fusion positive cholangiocarcinoma

被引：5
|
作者：
Goyal, Lipika [1 ]
Liu, Leah Y. [1 ]
Lennerz, Jochen K. [1 ]
Harding, James J. [2 ]
Huang, Jerry [3 ]
Winkler, Robert [3 ]
Hiroshi, Hirai [4 ]
Ting, David T. [1 ]
Juric, Dejan [1 ]
Corcoran, Ryan B. [1 ]
El-Bardeesy, Nabeel [1 ]
Zhu, Andrew X. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Taiho Oncol Inc, Princeton, NJ USA
[4] Taiho Pharmaceut Co Ltd, Tokyo, Japan
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-LB-092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-092
引用
收藏
页数：2
相关论文
共 23 条
  • [21] Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Harding, J.
    Perez, C.
    Kato, S.
    Sharma, M.
    Garmezy, B.
    Quah, C.
    Tam, B.
    Severson, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S63 - S64
  • [22] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
    Harding, James J.
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Garmezy, Benjamin
    Quah, Cheng Seok
    Tam, Betty
    Severson, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS637 - TPS637
  • [23] PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement.
    Abou-Alfa, Ghassan K.
    Borbath, Ivan
    Roychowdhury, Sameek
    Goyal, Lipika
    Lamarca, Angela
    Macarulla, Teresa
    Shroff, Rachna T.
    Oh, Do-Youn
    Javle, Milind M.
    Tamas, Catalin
    Savastano, David M.
    Van Veenhuyzen, David Friedrich
    Xu, Cindy
    Solanas, Jacki
    Freas, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 516 - 516
123